Latest Information Update: 23 Dec 2002
At a glance
- Originator Purdue Pharma
- Mechanism of Action Nociceptin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Dec 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
- 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
- 06 May 1999 CO 106284 has been identified as a lead compound from the research programme for nociceptin antagonists